ERBB2 and neoplasm: Next, we investigated whether HER2-DC1 i.t. combined with anti-HER2 antibodies treatment show superior antitumor effects compared with HER2-DC1 s.c. combined with anti-HER2 antibodies in the HER2pos TUBO tumor model.